Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
16.93
-0.12 (-0.73%)
Streaming Delayed Price
Updated: 12:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
June 26, 2025
Via
Benzinga
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
June 25, 2025
Via
The Motley Fool
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
June 16, 2025
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
June 06, 2025
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Via
Benzinga
How Do Investors Really Feel About Teva Pharmaceutical Indus?
June 05, 2025
Via
Benzinga
Where Teva Pharmaceutical Indus Stands With Analysts
May 28, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
May 07, 2025
Via
Benzinga
Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus
March 06, 2025
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
June 04, 2025
Via
Benzinga
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
May 29, 2025
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.
Via
Benzinga
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
May 28, 2025
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Government
Why Is Teva Stock Trading Higher On Tuesday?
May 27, 2025
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via
Benzinga
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
May 12, 2025
Via
The Motley Fool
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
May 12, 2025
Via
Benzinga
This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
May 12, 2025
Via
Benzinga
Why Teva Pharmaceutical Stock Is Soaring Today
May 07, 2025
Via
The Motley Fool
Topics
Earnings
Stocks
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
May 07, 2025
Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations.
Via
Benzinga
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report
May 07, 2025
Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast.
Via
Investor's Business Daily
Topics
Government
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
May 06, 2025
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.
Via
Benzinga
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
May 05, 2025
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
Via
Benzinga
What Does the Market Think About Teva Pharmaceutical Indus?
April 30, 2025
Via
Benzinga
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now
April 21, 2025
Short-term uncertainty has led to a golden opportunity for long-term investors.
Via
The Motley Fool
Topics
Economy
Government
Stocks
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
April 13, 2025
Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.
Via
The Motley Fool
Topics
Government
Stocks
World Trade
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
April 09, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via
Investor's Business Daily
Topics
Government
Stocks
World Trade
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now
March 28, 2025
Via
The Motley Fool
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks
March 24, 2025
Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.
Via
The Motley Fool
Topics
Artificial Intelligence
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
March 19, 2025
Via
The Motley Fool
Is SoundHound AI Stock a Buy Now?
March 05, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
February 24, 2025
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Via
Benzinga
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
February 20, 2025
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.